{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T07:24:57Z","timestamp":1778743497583,"version":"3.51.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,13]]},"DOI":"10.7759\/cureus.84070","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T06:33:46Z","timestamp":1747204426000},"source":"Crossref","is-referenced-by-count":1,"title":["Expert Consensus Guidance on the Management of Chemotherapy-Induced Nausea and Vomiting: An Indian Perspective"],"prefix":"10.7759","author":[{"given":"Boman","family":"Dhabhar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabrajya N","family":"Mahapatra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vamshi M","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jatin","family":"Sarin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara Chand","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aseem","family":"Samar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bivas","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditya","family":"Murli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Kota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suyash","family":"Bharat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richa","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100278","article-title":"Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends","volume":"26","author":"Gupta K","year":"2021","unstructured":"Gupta K, Walton R, Kataria SP. Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends. Cancer Treat Res Commun. 2021, 26:10.1016\/j.ctarc.2020.100278","journal-title":"Cancer Treat Res Commun"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1726136","article-title":"Chemotherapy-induced nausea and vomiting (CINV) with GI cancer chemotherapy: do we need CINV risk score over and above antiemetic guidelines in prescribing antiemetic regime?","volume":"9","author":"D'Souza A","year":"2020","unstructured":"D'Souza A, Pawar D, Ramaswamy A, et al.. Chemotherapy-induced nausea and vomiting (CINV) with GI cancer chemotherapy: do we need CINV risk score over and above antiemetic guidelines in prescribing antiemetic regime?. South Asian J Cancer. 2020, 9:240-4. 10.1055\/s-0041-1726136","journal-title":"South Asian J Cancer"},{"key":"ref3","unstructured":"Nausea and vomiting related to cancer treatment (PDQ) - health professional version. (2023). Accessed. March 30, 2025: https:\/\/www.cancer.gov\/about-cancer\/treatment\/side-effects\/nausea\/nausea-hp-pdq."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-016-1069-7","article-title":"Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan","volume":"22","author":"Tamura K","year":"2017","unstructured":"Tamura K, Aiba K, Saeki T, et al.. Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan. Int J Clin Oncol. 2017, 22:405-12. 10.1007\/s10147-016-1069-7","journal-title":"Int J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00019","article-title":"Delayed chemotherapy-induced nausea and vomiting: pathogenesis, incidence, and current management","volume":"8","author":"Rapoport BL","year":"2017","unstructured":"Rapoport BL. Delayed chemotherapy-induced nausea and vomiting: pathogenesis, incidence, and current management. Front Pharmacol. 2017, 8:10.3389\/fphar.2017.00019","journal-title":"Front Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4464-y","article-title":"ASCO, NCCN, MASCC\/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients","volume":"27","author":"Razvi Y","year":"2019","unstructured":"Razvi Y, Chan S, McFarlane T, et al.. ASCO, NCCN, MASCC\/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer. 2019, 27:87-95. 10.1007\/s00520-018-4464-y","journal-title":"Support Care Cancer"},{"key":"ref7","unstructured":"National Comprehensive Cancer Network. (2024). Accessed. March 30, 2025: https:\/\/www.nccn.org\/login?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw270","article-title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila F","year":"2016","unstructured":"Roila F, Molassiotis A, Herrstedt J, et al.. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016, 27:119-33. 10.1093\/annonc\/mdw270","journal-title":"Ann Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00400","article-title":"Expert consensus on effective management of chemotherapy-induced nausea and vomiting: an Indian perspective","volume":"10","author":"Vaid AK","year":"2020","unstructured":"Vaid AK, Gupta S, Doval DC, et al.. Expert consensus on effective management of chemotherapy-induced nausea and vomiting: an Indian perspective. Front Oncol. 2020, 10:10.3389\/fonc.2020.00400","journal-title":"Front Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.2016.006023","article-title":"Survey of implementation of antiemetic prescription standards in Indian oncology practices and its adherence to the American Society of Clinical Oncology antiemetic clinical guideline","volume":"3","author":"Patil V","year":"2016","unstructured":"Patil V, Noronha V, Joshi A, et al.. Survey of implementation of antiemetic prescription standards in Indian oncology practices and its adherence to the American Society of Clinical Oncology antiemetic clinical guideline. J Glob Oncol. 2016, 3:346-59. 10.1200\/JGO.2016.006023","journal-title":"J Glob Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh PJ","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, et al.. Antiemetics: ASCO guideline update. J Clin Oncol. 2020, 38:2782-97. 10.1200\/JCO.20.01296","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.28945\/3561","article-title":"Delphi panels: research design, procedures, advantages, and challenges","volume":"11","author":"Avella JR","year":"2016","unstructured":"Avella JR. Delphi panels: research design, procedures, advantages, and challenges. Int J Doctoral Stud. 2016, 11:305-21. 10.28945\/3561","journal-title":"Int J Doctoral Stud"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1378\/chest.129.1.174","article-title":"Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force","volume":"129","author":"Guyatt G","year":"2006","unstructured":"Guyatt G, Gutterman D, Baumann MH, et al.. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest. 2006, 129:174-81. 10.1378\/chest.129.1.174","journal-title":"Chest"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.suponc.2011.10.007","article-title":"Chemotherapy-induced nausea and vomiting in Asian women with breast cancer receiving anthracycline-based adjuvant chemotherapy","volume":"10","author":"Bourdeanu L","year":"2012","unstructured":"Bourdeanu L, Frankel P, Yu W, et al.. Chemotherapy-induced nausea and vomiting in Asian women with breast cancer receiving anthracycline-based adjuvant chemotherapy. J Support Oncol. 2012, 10:149-54. 10.1016\/j.suponc.2011.10.007","journal-title":"J Support Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.11.012","article-title":"A review of the literature on the relationships between genetic polymorphisms and chemotherapy-induced nausea and vomiting","volume":"121","author":"Singh KP","year":"2018","unstructured":"Singh KP, Dhruva AA, Flowers E, Kober KM, Miaskowski C. A review of the literature on the relationships between genetic polymorphisms and chemotherapy-induced nausea and vomiting. Crit Rev Oncol Hematol. 2018, 121:51-61. 10.1016\/j.critrevonc.2017.11.012","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S329257","article-title":"An update in our understanding of the relationships between gene polymorphisms and chemotherapy-induced nausea and vomiting","volume":"14","author":"Jin Y","year":"2021","unstructured":"Jin Y, Li X, Jiang C, et al.. An update in our understanding of the relationships between gene polymorphisms and chemotherapy-induced nausea and vomiting. Int J Gen Med. 2021, 14:5879-92. 10.2147\/IJGM.S329257","journal-title":"Int J Gen Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-013-0312-x","article-title":"Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists?","volume":"15","author":"Trammel M","year":"2013","unstructured":"Trammel M, Roederer M, Patel J, McLeod H. Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists?. Curr Oncol Rep. 2013, 15:276-85. 10.1007\/s11912-013-0312-x","journal-title":"Curr Oncol Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3338-4","article-title":"Examining racial variation in antiemetic use and post-chemotherapy health care utilization for nausea and vomiting among breast cancer patients","volume":"24","author":"Check DK","year":"2016","unstructured":"Check DK, Reeder-Hayes KE, Zullig LL, Weinberger M, Basch EM, Dusetzina SB. Examining racial variation in antiemetic use and post-chemotherapy health care utilization for nausea and vomiting among breast cancer patients. Support Care Cancer. 2016, 24:4839-47. 10.1007\/s00520-016-3338-4","journal-title":"Support Care Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70117-2","article-title":"Delivery of affordable and equitable cancer care in India","volume":"15","author":"Pramesh CS","year":"2014","unstructured":"Pramesh CS, Badwe RA, Borthakur BB, et al.. Delivery of affordable and equitable cancer care in India. Lancet Oncol. 2014, 15:223-33. 10.1016\/S1470-2045(14)70117-2","journal-title":"Lancet Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1127","article-title":"Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: a quantitative market research-based survey","volume":"1","author":"Aapro M","year":"2018","unstructured":"Aapro M, Ruffo P, Panteri R, Costa S, Piovesana V. Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: a quantitative market research-based survey. Cancer Rep (Hoboken). 2018, 1:10.1002\/cnr2.1127","journal-title":"Cancer Rep (Hoboken)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2174\/1568009622666220513094352","article-title":"Netupitant-palonosetron (NEPA) for preventing chemotherapy-induced nausea and vomiting: from clinical trials to daily practice","volume":"22","author":"Aapro M","year":"2022","unstructured":"Aapro M, Jordan K, Scott\u00e9 F, Celio L, Karthaus M, Roeland E. Netupitant-palonosetron (NEPA) for preventing chemotherapy-induced nausea and vomiting: from clinical trials to daily practice. Curr Cancer Drug Targets. 2022, 22:806-24. 10.2174\/1568009622666220513094352","journal-title":"Curr Cancer Drug Targets"},{"key":"ref22","article-title":"Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies","volume":"23","author":"Adel N","year":"2017","unstructured":"Adel N. Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies. Am J Manag Care. 2017, 23:259-65.","journal-title":"Am J Manag Care"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-3585-z","article-title":"Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists","volume":"25","author":"Bo\u0161njak SM","year":"2017","unstructured":"Bo\u0161njak SM, Gralla RJ, Schwartzberg L. Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists. Support Care Cancer. 2017, 25:1661-71. 10.1007\/s00520-017-3585-z","journal-title":"Support Care Cancer"},{"key":"ref24","article-title":"Chemotherapy-induced nausea and vomiting: optimizing prevention and management","volume":"5","author":"Rao KV","year":"2012","unstructured":"Rao KV, Faso A. Chemotherapy-induced nausea and vomiting: optimizing prevention and management. Am Health Drug Benefits. 2012, 5:232-40.","journal-title":"Am Health Drug Benefits"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2016.17.4.1661","article-title":"Efficacy and safety of neurokinin-1 receptor antagonists for prevention of chemotherapy-induced nausea and vomiting: systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Yuan DM","year":"2016","unstructured":"Yuan DM, Li Q, Zhang Q, et al.. Efficacy and safety of neurokinin-1 receptor antagonists for prevention of chemotherapy-induced nausea and vomiting: systematic review and meta-analysis of randomized controlled trials. Asian Pac J Cancer Prev. 2016, 17:1661-75. 10.7314\/apjcp.2016.17.4.1661","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0229","article-title":"Aprepitant and fosaprepitant: a 10-year review of efficacy and safety","volume":"20","author":"Aapro M","year":"2015","unstructured":"Aapro M, Carides A, Rapoport BL, Schmoll HJ, Zhang L, Warr D. Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. Oncologist. 2015, 20:450-8. 10.1634\/theoncologist.2014-0229","journal-title":"Oncologist"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs335","article-title":"Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review","volume":"104","author":"dos Santos LV","year":"2012","unstructured":"dos Santos LV, Souza FH, Brunetto AT, Sasse AD, Lima JP. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J Natl Cancer Inst. 2012, 104:1280-92. 10.1093\/jnci\/djs335","journal-title":"J Natl Cancer Inst"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-3857-7","article-title":"Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy? - A systematic review and meta-analysis","volume":"26","author":"Jordan K","year":"2018","unstructured":"Jordan K, Bl\u00e4ttermann L, Hinke A, M\u00fcller-Tidow C, Jahn F. Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy? - A systematic review and meta-analysis. Support Care Cancer. 2018, 26:21-32. 10.1007\/s00520-017-3857-7","journal-title":"Support Care Cancer"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4103\/2278-330X.149923","article-title":"Open-label observational study to assess the efficacy and safety of aprepitant for chemotherapy-induced nausea and vomiting prophylaxis in Indian patients receiving chemotherapy with highly emetogenic chemotherapy\/moderately emetogenic chemotherapy regimens","volume":"4","author":"Hingmire S","year":"2015","unstructured":"Hingmire S, Raut N. Open-label observational study to assess the efficacy and safety of aprepitant for chemotherapy-induced nausea and vomiting prophylaxis in Indian patients receiving chemotherapy with highly emetogenic chemotherapy\/moderately emetogenic chemotherapy regimens. South Asian J Cancer. 2015, 4:7-10. 10.4103\/2278-330X.149923","journal-title":"South Asian J Cancer"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2015.567","article-title":"Comparative evaluation of triplet antiemetic schedule versus doublet antiemetic schedule in chemotherapy-induced emesis in head and neck cancer patients","volume":"9","author":"Kaushal P","year":"2015","unstructured":"Kaushal P, Atri R, Soni A, Kaushal V. Comparative evaluation of triplet antiemetic schedule versus doublet antiemetic schedule in chemotherapy-induced emesis in head and neck cancer patients. Ecancermedicalscience. 2015, 9:10.3332\/ecancer.2015.567","journal-title":"Ecancermedicalscience"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.4103\/0019-509X.123580","article-title":"A phase 3, randomized, double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting: results of an Indian population subanalysis","volume":"50","author":"Maru A","year":"2013","unstructured":"Maru A, Gangadharan VP, Desai CJ, Mohapatra RK, Carides AD. A phase 3, randomized, double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting: results of an Indian population subanalysis. Indian J Cancer. 2013, 50:285-91. 10.4103\/0019-509X.123580","journal-title":"Indian J Cancer"},{"key":"ref32","article-title":"A retrospective case cohort analysis on the clinical utility of fosaprepitant in CINV prophylaxis in day care center of South India","volume":"2","author":"Ramesh AC","year":"2019","unstructured":"Ramesh AC, Bhagat S. A retrospective case cohort analysis on the clinical utility of fosaprepitant in CINV prophylaxis in day care center of South India. J Curr Oncol. 2019, 2:1-6.","journal-title":"J Curr Oncol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.2147\/CE.S203634","article-title":"Management of chemotherapy-induced nausea and vomiting (CINV): a short review on the role of netupitant-palonosetron (NEPA)","volume":"15","author":"Lorusso V","year":"2020","unstructured":"Lorusso V, Russo A, Giotta F, Codega P. Management of chemotherapy-induced nausea and vomiting (CINV): a short review on the role of netupitant-palonosetron (NEPA). Core Evid. 2020, 15:21-9. 10.2147\/CE.S203634","journal-title":"Core Evid"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx698","article-title":"A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)","volume":"29","author":"Zhang L","year":"2018","unstructured":"Zhang L, Lu S, Feng J, et al.. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Ann Oncol. 2018, 29:452-8. 10.1093\/annonc\/mdx698","journal-title":"Ann Oncol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1188\/18.CJON.E52-E63","article-title":"Fixed combination antiemetic: a literature review on prevention of chemotherapy-induced nausea and vomiting using netupitant\/palonosetron","volume":"22","author":"Clark-Snow RA","year":"2018","unstructured":"Clark-Snow RA, Vidall C, B\u00f6rjeson S, Jahn P. Fixed combination antiemetic: a literature review on prevention of chemotherapy-induced nausea and vomiting using netupitant\/palonosetron. Clin J Oncol Nurs. 2018, 22:52-63. 10.1188\/18.CJON.E52-E63","journal-title":"Clin J Oncol Nurs"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v11.i8.606","article-title":"Effectiveness of a novel, fixed dose combination of netupitant and palonosetron in prevention of chemotherapy induced nausea and vomiting: a real-life study from India","volume":"11","author":"Vaswani B","year":"2020","unstructured":"Vaswani B, Bhagat S, Patil S, Barkate H. Effectiveness of a novel, fixed dose combination of netupitant and palonosetron in prevention of chemotherapy induced nausea and vomiting: a real-life study from India. World J Clin Oncol. 2020, 11:606-13. 10.5306\/wjco.v11.i8.606","journal-title":"World J Clin Oncol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08342-1","article-title":"The effectiveness of NEPA in the prevention of chemotherapy-induced nausea vomiting among chemo naive patients in an Indian setting","volume":"21","author":"Vaswani B","year":"2021","unstructured":"Vaswani B, Dattatreya PS, Bhagat S, Patil S, Barkate H. The effectiveness of NEPA in the prevention of chemotherapy-induced nausea vomiting among chemo naive patients in an Indian setting. BMC Cancer. 2021, 21:10.1186\/s12885-021-08342-1","journal-title":"BMC Cancer"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29094","article-title":"The effectiveness of an oral fixed-dose combination of netupitant and palonosetron (NEPA) in patients with multiple risk factors for chemotherapy-induced nausea and vomiting: a multicenter, observational Indian study","volume":"14","author":"Vaswani B","year":"2022","unstructured":"Vaswani B, Dattatreya PS, Barkate H, Bhagat SB, Patil S, Jadhav AY. The effectiveness of an oral fixed-dose combination of netupitant and palonosetron (NEPA) in patients with multiple risk factors for chemotherapy-induced nausea and vomiting: a multicenter, observational Indian study. Cureus. 2022, 14:10.7759\/cureus.29094","journal-title":"Cureus"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6121","article-title":"Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy","volume":"12","author":"Zelek L","year":"2023","unstructured":"Zelek L, Navari R, Aapro M, Scott\u00e9 F. Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Cancer Med. 2023, 12:15769-76. 10.1002\/cam4.6121","journal-title":"Cancer Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0023","article-title":"Single-dose netupitant\/palonosetron\u00a0versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a\u00a0pooled analysis","volume":"17","author":"Navari RM","year":"2021","unstructured":"Navari RM, Binder G, Bonizzoni E, Clark-Snow R, Olivari S, Roeland EJ. Single-dose netupitant\/palonosetron\u00a0versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a\u00a0pooled analysis. Future Oncol. 2021, 17:3027-35. 10.2217\/fon-2021-0023","journal-title":"Future Oncol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2175-6","article-title":"Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials","volume":"22","author":"Popovic M","year":"2014","unstructured":"Popovic M, Warr DG, Deangelis C, et al.. Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer. 2014, 22:1685-97. 10.1007\/s00520-014-2175-6","journal-title":"Support Care Cancer"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2017\/25129.9818","article-title":"Comparison of antiemetic effectiveness of palonosetron versus ondansetron in patients on cancer chemotherapy: a prospective observational study in South Indians","volume":"11","author":"Parathoduvil AA","year":"2017","unstructured":"Parathoduvil AA, Sisupalan A, Rema PL. Comparison of antiemetic effectiveness of palonosetron versus ondansetron in patients on cancer chemotherapy: a prospective observational study in South Indians. J Clin Diagn Res. 2017, 11:10-4. 10.7860\/JCDR\/2017\/25129.9818","journal-title":"J Clin Diagn Res"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13888","article-title":"A pragmatic study evaluating NEPA versus aprepitant for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy","volume":"26","author":"Zelek L","year":"2021","unstructured":"Zelek L, Debourdeau P, Bourgeois H, et al.. A pragmatic study evaluating NEPA versus aprepitant for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Oncologist. 2021, 26:1870-9. 10.1002\/onco.13888","journal-title":"Oncologist"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13851","article-title":"Dexamethasone-sparing regimens with oral netupitant and palonosetron for the prevention of emesis caused by high-dose cisplatin: a randomized noninferiority study","volume":"26","author":"Celio L","year":"2021","unstructured":"Celio L, Cortinovis D, Cogoni AA, et al.. Dexamethasone-sparing regimens with oral netupitant and palonosetron for the prevention of emesis caused by high-dose cisplatin: a randomized noninferiority study. Oncologist. 2021, 26:1854-61. 10.1002\/onco.13851","journal-title":"Oncologist"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2020.108738","article-title":"Effects of synthetic glucocorticoids on breast cancer progression","volume":"164","author":"Pang JM","year":"2020","unstructured":"Pang JM, Huang YC, Sun SP, et al.. Effects of synthetic glucocorticoids on breast cancer progression. Steroids. 2020, 164:10.1016\/j.steroids.2020.108738","journal-title":"Steroids"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.455","article-title":"Dexamethasone mediates pancreatic cancer progression by glucocorticoid receptor, TGF\u03b2 and JNK\/AP-1","volume":"8","author":"Liu L","year":"2017","unstructured":"Liu L, Aleksandrowicz E, Sch\u00f6nsiegel F, et al.. Dexamethasone mediates pancreatic cancer progression by glucocorticoid receptor, TGF\u03b2 and JNK\/AP-1. Cell Death Dis. 2017, 8:10.1038\/cddis.2017.455","journal-title":"Cell Death Dis"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-2777459\/v1","article-title":"Efficacy of olanzapine, netupitant, and palonosetron in controlling nausea and vomiting associated with highly emetogenic chemotherapy in patients with breast cancer (OLNEPA)","volume":"40","author":"de Rebou\u00e7as CV","year":"2022","unstructured":"de Rebou\u00e7as CV, de Brito Alves R, Yamada AM, Giglio AD, Cruz FJ. Efficacy of olanzapine, netupitant, and palonosetron in controlling nausea and vomiting associated with highly emetogenic chemotherapy in patients with breast cancer (OLNEPA). J Clin Oncol. 2022, 40:10.21203\/rs.3.rs-2777459\/v1","journal-title":"J Clin Oncol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0909-2","article-title":"Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin's lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study","volume":"55","author":"Di Renzo N","year":"2020","unstructured":"Di Renzo N, Musso M, Scim\u00e8 R, et al.. Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin's lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study. Bone Marrow Transplant. 2020, 55:2114-20. 10.1038\/s41409-020-0909-2","journal-title":"Bone Marrow Transplant"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102512","article-title":"Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: a systematic review and network meta-analysis","volume":"115","author":"Filetti M","year":"2023","unstructured":"Filetti M, Lombardi P, Giusti R, et al.. Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: a systematic review and network meta-analysis. Cancer Treat Rev. 2023, 115:10.1016\/j.ctrv.2023.102512","journal-title":"Cancer Treat Rev"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-08224-1","article-title":"2023 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting","volume":"32","author":"Rapoport BL","year":"2023","unstructured":"Rapoport BL, Herrstedt J, Snow RC, Radhakrishnan V, Saito M, Navari RM, Smit T. 2023 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer. 2023, 32:10.1007\/s00520-023-08224-1","journal-title":"Support Care Cancer"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3439707","article-title":"The efficacy, safety, and cost benefit of olanzapine versus aprepitant in highly emetogenic chemotherapy: a pilot study from South India","volume":"2016","author":"Babu G","year":"2016","unstructured":"Babu G, Saldanha SC, Chinnagiriyappa LK, et al.. The efficacy, safety, and cost benefit of olanzapine versus aprepitant in highly emetogenic chemotherapy: a pilot study from South India. Chemother Res Pract. 2016, 2016:10.1155\/2016\/3439707","journal-title":"Chemother Res Pract"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3386-9","article-title":"Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study","volume":"25","author":"Mukhopadhyay S","year":"2017","unstructured":"Mukhopadhyay S, Kwatra G, Alice KP, Badyal D. Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study. Support Care Cancer. 2017, 25:145-54. 10.1007\/s00520-016-3386-9","journal-title":"Support Care Cancer"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000002737","article-title":"Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting in children: a systematic review and meta-analysis of randomized controlled trials","volume":"45","author":"Meena JP","year":"2023","unstructured":"Meena JP, Gupta AK, Jat KR, Anandani G, Sasidharan A, Tanwar P. Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting in children: a systematic review and meta-analysis of randomized controlled trials. J Pediatr Hematol Oncol. 2023, 45:361-9. 10.1097\/MPH.0000000000002737","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00871","article-title":"Olanzapine for prevention of vomiting in children and adolescents receiving highly emetogenic chemotherapy: investigator-initiated, randomized, open-label trial","volume":"38","author":"Naik RD","year":"2020","unstructured":"Naik RD, Sreenivas V, Singh V, Pillai AS, Dhawan D, Bakhshi S. Olanzapine for prevention of vomiting in children and adolescents receiving highly emetogenic chemotherapy: investigator-initiated, randomized, open-label trial. J Clin Oncol. 2020, 38:3785-93. 10.1200\/JCO.20.00871","journal-title":"J Clin Oncol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.2145","article-title":"LBA64 Olanzapine, an alternative to dexamethasone for preventing nausea and vomiting induced by cisplatin-based doublet highly emetogenic chemotherapy: a non-inferiority, prospective, multi-centered, randomized, controlled, phase III clinical trial","volume":"32","author":"Liu Z","year":"2021","unstructured":"Liu Z, Zhou Y, Feng WN, et al.. LBA64 Olanzapine, an alternative to dexamethasone for preventing nausea and vomiting induced by cisplatin-based doublet highly emetogenic chemotherapy: a non-inferiority, prospective, multi-centered, randomized, controlled, phase III clinical trial. Ann Oncol. 2021, 32:10.1016\/j.annonc.2021.08.2145","journal-title":"Ann Oncol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS12133","article-title":"Olanzapine or dexamethasone, with 5-HT3 receptor antagonist and NK-1 receptor antagonist, to prevent nausea and vomiting induced by cisplatin-based doublet chemotherapy: a non-inferiority, prospective, multi-centered, randomized, controlled, phase III clinical trial","volume":"39","author":"Liu Z","year":"2021","unstructured":"Liu Z, Zhou Y, Yang S, et al.. Olanzapine or dexamethasone, with 5-HT3 receptor antagonist and NK-1 receptor antagonist, to prevent nausea and vomiting induced by cisplatin-based doublet chemotherapy: a non-inferiority, prospective, multi-centered, randomized, controlled, phase III clinical trial. J Clin Oncol. 2021, 39:10.1200\/JCO.2021.39.15_suppl.TPS12133","journal-title":"J Clin Oncol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.373","article-title":"Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study","volume":"4","author":"Kimura H","year":"2015","unstructured":"Kimura H, Yamamoto N, Shirai T, et al.. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study. Cancer Med. 2015, 4:333-41. 10.1002\/cam4.373","journal-title":"Cancer Med"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-4645-3","article-title":"One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients","volume":"27","author":"Badalamenti G","year":"2019","unstructured":"Badalamenti G, Incorvaia L, Messina C, et al.. One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients. Support Care Cancer. 2019, 27:3593-7. 10.1007\/s00520-019-4645-3","journal-title":"Support Care Cancer"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.198","article-title":"Netupitant PET imaging and ADME studies in humans","volume":"54","author":"Spinelli T","year":"2013","unstructured":"Spinelli T, Calcagnile S, Giuliano C, et al.. Netupitant PET imaging and ADME studies in humans. J Clin Pharmacol. 2013, 54:97-108. 10.1002\/jcph.198","journal-title":"J Clin Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/357582-expert-consensus-guidance-on-the-management-of-chemotherapy-induced-nausea-and-vomiting-an-indian-perspective","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T06:33:49Z","timestamp":1747204429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/357582-expert-consensus-guidance-on-the-management-of-chemotherapy-induced-nausea-and-vomiting-an-indian-perspective"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":59,"URL":"https:\/\/doi.org\/10.7759\/cureus.84070","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,13]]}}}